FDA places par­tial clin­i­cal hold on David Hung biotech af­ter cer­tain can­cer pa­tients ex­pe­ri­ence eye in­flam­ma­tion

Two and a half years af­ter set­ting out on an­oth­er for­ay in­to on­col­o­gy R&D, a biotech head­ed by David Hung — of Medi­va­tion fame — has run in­to its first set­back.

San Fran­cis­co-based Nu­va­tion Bio an­nounced ear­ly Mon­day the FDA placed a par­tial clin­i­cal hold on a Phase I dose-es­ca­la­tion study of NUV-422, its CDK in­hibitor pro­gram for cer­tain types of sol­id tu­mors. The tri­al be­gan en­rolling pa­tients in De­cem­ber 2020, and, ac­cord­ing to Nu­va­tion, re­searchers were in the mid­dle of ex­plor­ing dose es­ca­la­tion and defin­ing the max­i­mum dose tol­er­a­ble in pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER